Gapping down
In reaction to disappointing earnings/guidance: MOBI -12%, TOUR -5.6%
M&A news: SO -1.6% (acquiring GAS)
Select fan favorites showing weakness: FIT -14.5%, SHAK -13.6%, CYBR -13.5%, GPRO -11.9%, SWKS -11.9%, FEYE -11.5%, NFLX -10.1%, MBLY -9.1%, SBUX -7.5%, PANW -7.5%, SUNE -7.3%, TSLA -7.1%, TWTR -7.1%, AAPL -6.5%
In reaction to disappointing earnings/guidance: MOBI -12%, TOUR -5.6%
M&A news: SO -1.6% (acquiring GAS)
Select fan favorites showing weakness: FIT -14.5%, SHAK -13.6%, CYBR -13.5%, GPRO -11.9%, SWKS -11.9%, FEYE -11.5%, NFLX -10.1%, MBLY -9.1%, SBUX -7.5%, PANW -7.5%, SUNE -7.3%, TSLA -7.1%, TWTR -7.1%, AAPL -6.5%
Select China related names showing weakness after Shanhai was down 8.5% overnight: NQ -21%, BTU -18.5%, QIHU -16%, SFUN -14.1%, WBAI -12.9%, CSIQ -11.8%, JD -10.2%, BITA -9.6%, BABA -9.1%, CHL -8.5%, SPWR -8.3%, MGM -8.2%, WUBA -8.1%, SINA -8.1%
Select metals/mining stocks trading lower: CLF -11.2%, FCX -7.8%, X -7%, BHP -5.9%, MT -5.7%
Select oil/gas related names showing early weakness: PACD -12.3%, PBR -9.5%, LINE -5.4%, HAL -5.3%
Other news: VTL -80.8% (nnounces that topline results of its VTI-208 trial fail to achieve primary or secondary endpoints of improvement in overall survival; ), NBG -13.5% (cont uncertainty in Greece after snap elections called), DGLY -10.5% (Bloomberg reports that Sony (SNE) is considering entering drone market), RAD -9.7% (still checking), ESLT -7% (still checking, but was awarded $27 million contract to supply command and control and artillery systems to an Asia-Pacific Country), HLT -6.1% (still checking), GALE -5.2% (announce?s that the Independent Data Monitoring Committee has recommended to GALE that it can reduce the cardiac toxicity monitoring for patients in its NeuVax Phase 3 PRESENT clinical trial), CIE -3.3% (to sell its 40% participating interest in Blocks 21/09 and 20/11 offshore Angola for $1.75 bln to Empresa Pública), ALKS -1.7% (announces that FDA has advised it will not be able to complete its review of the New Drug Application for ARISTADA for the treatment of schizophrenia)
Analyst comments: WLL -10.7% (downgraded to Neutral at BofA/Merrill ), SPLK -8.3% (downgraded to Hold at Summit Research), GM -6.8% (resumed with a Underweight at Morgan Stanley), MRO -6.7% (downgraded to Neutral at BofA/Merrill ), KGC -1.9% (downgraded to Underperform at RBC Capital Mkts)
Other news: VTL -80.8% (nnounces that topline results of its VTI-208 trial fail to achieve primary or secondary endpoints of improvement in overall survival; ), NBG -13.5% (cont uncertainty in Greece after snap elections called), DGLY -10.5% (Bloomberg reports that Sony (SNE) is considering entering drone market), RAD -9.7% (still checking), ESLT -7% (still checking, but was awarded $27 million contract to supply command and control and artillery systems to an Asia-Pacific Country), HLT -6.1% (still checking), GALE -5.2% (announce?s that the Independent Data Monitoring Committee has recommended to GALE that it can reduce the cardiac toxicity monitoring for patients in its NeuVax Phase 3 PRESENT clinical trial), CIE -3.3% (to sell its 40% participating interest in Blocks 21/09 and 20/11 offshore Angola for $1.75 bln to Empresa Pública), ALKS -1.7% (announces that FDA has advised it will not be able to complete its review of the New Drug Application for ARISTADA for the treatment of schizophrenia)
Analyst comments: WLL -10.7% (downgraded to Neutral at BofA/Merrill ), SPLK -8.3% (downgraded to Hold at Summit Research), GM -6.8% (resumed with a Underweight at Morgan Stanley), MRO -6.7% (downgraded to Neutral at BofA/Merrill ), KGC -1.9% (downgraded to Underperform at RBC Capital Mkts)